Warning: The NCBI web site requires JavaScript to function. more...

My NCBI Sign In

Blood. 2005 Dec 15;106(13):4086-92. Epub 2005 Aug 30.

Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia.

Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G, Luongo JL, Danet-Desnoyers GA, Bonnet D.

Source

Haematopoietic Stem Cell Laboratory, Cancer Research UK, London Research Institute.

Abstract

Human hematopoietic stem cells (HSCs) are generally regarded as being devoid of the markers expressed by differentiated blood cells, the lineage-specific antigens. However, recent work suggests that genes associated with the myeloid lineage are transcribed in mouse HSCs. Here, we explore whether myeloid genes are actually translated in human HSCs. We show that CD33, CD13, and CD123, well-established myeloid markers, are expressed on human long-term repopulating cells from cord blood and bone marrow. In addition, we demonstrate that nonobese diabetic/severe combined immunodeficiency (NOD/SCID) leukemia-initiating cells (SL-ICs) are restricted to the CD33+ fraction in 11 of 12 acute myeloid leukemia (AML) samples studied, indicating that leukemic stem cells (LSCs) express this antigen. This study changes our view of HSCs and the process of differentiation. Furthermore, based on the phenotypic similarity of HSCs and LSCs, our data provide support for the hypothesis that AML derives from an HSC. Our findings also provide a challenge to contemporary attempts to improve the outcome of AML using myeloid antigen-targeted therapies, given the potential for HSC killing.

PMID:: 16131573; [PubMed - indexed for MEDLINE]
PMCID: PMC1895250

Free PMC Article

Images from this publication.See all images (4) Free text

Figure 2.

Figure 4.

Figure 3.

Figure 1.

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

HL64856-01/HL/NHLBI NIH HHS/United States

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Click here to read

Click here to read

Related citations

Implications of the expression of myeloid markers on normal and leukemic stem cells. [Cell Cycle. 2006]
Implications of the expression of myeloid markers on normal and leukemic stem cells.
Pearce DJ, Taussig DC, Bonnet D. Cell Cycle. 2006 Feb; 5(3):271-3. Epub 2006 Mar 8.
Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. [Cell Stem Cell. 2009]
Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, et al. Cell Stem Cell. 2009 Jul 2; 5(1):31-42.
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. [Nat Med. 1997]
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.
Bonnet D, Dick JE. Nat Med. 1997 Jul; 3(7):730-7.
Review The leukemic stem cell niche: current concepts and therapeutic opportunities. [Blood. 2009]
Review The leukemic stem cell niche: current concepts and therapeutic opportunities.
Lane SW, Scadden DT, Gilliland DG. Blood. 2009 Aug 6; 114(6):1150-7. Epub 2009 Apr 28.
Review Acute myeloid leukemia stem cells. [Ann N Y Acad Sci. 2005]
Review Acute myeloid leukemia stem cells.
Dick JE. Ann N Y Acad Sci. 2005 Jun; 1044:1-5.

See reviews... See all...

Cited by 17 PubMed Central articles

In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia. [Adv Hematol. 2012]
In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia.
Dutour A, Marin V, Pizzitola I, Valsesia-Wittmann S, Lee D, Yvon E, Finney H, Lawson A, Brenner M, Biondi A, et al. Adv Hematol. 2012; 2012:683065. Epub 2012 Jan 5.
CD34+/CD38- stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. [Haematologica. 2012]
CD34+/CD38- stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
Herrmann H, Cerny-Reiterer S, Gleixner KV, Blatt K, Herndlhofer S, Rabitsch W, Jäger E, Mitterbauer-Hohendanner G, Streubel B, Selzer E, et al. Haematologica. 2012 Feb; 97(2):219-26. Epub 2011 Oct 11.
Targeting leukemia stem cells: The new goal of therapy in adult acute myeloid leukemia. [World J Stem Cells. 2009]
Targeting leukemia stem cells: The new goal of therapy in adult acute myeloid leukemia.
Thomas X. World J Stem Cells. 2009 Dec 31; 1(1):49-54.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Hematopoietic stem cells express multiple myeloid markers: implications for the ...
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia.
Blood. 2005 Dec 15 ;106(13):4086-92. Epub 2005 Aug 30 .

PubMed
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications ...
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML.
Blood. 2006 Feb 1 ;107(3):1166-73. Epub 2005 Oct 18 .

PubMed
The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activat...
The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity.
Biol Chem. 2002 Jul-Aug ;383(7-8):1133-8.

PubMed
Comparative efficacy of famciclovir and valacyclovir for suppression of recurren...
Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding.
Sex Transm Dis. 2006 Sep ;33(9):529-33.

PubMed
In vivo formation of unstable heterokaryons after liver damage and hematopoietic...
In vivo formation of unstable heterokaryons after liver damage and hematopoietic stem cell/progenitor transplantation.
Stem Cells. 2006 Apr ;24(4):1104-12. Epub 2005 Nov 10 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

You are here: NCBI > Literature > PubMed

Write to the Help Desk